Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can early chemo beat the clock against colon cancer?

NCT ID NCT01460589

Disease control Sponsor: Kyungpook National University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether starting chemotherapy 10 to 14 days after surgery for stage III colon cancer is better than waiting the usual 2 weeks or more. About 300 patients are taking part to see if earlier treatment improves survival and lowers the chance of cancer coming back. The trial also checks for side effects and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
FOLFOX chemotherapy (oxaliplatin, leucovorin, 5-FU)
What this could lead to
If early chemotherapy works better, it could become a new standard to reduce cancer recurrence and improve survival for stage III colon cancer patients.
What could go wrong
This is a moderate-sized phase 3 trial, but results may not apply to all patients. Early chemo could increase side effects or complications without clear benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

303 people

The number who actually took part.

Started

Jan 2013

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Eligibility rule of enrollment * Rectal adenocarcinoma that were 15 cm or more from the anal verge * pathologically diagnosed stage II or III disease * patients who meet the discharge criteria within 10days after surgery * Patients with adequate hepatic, renal, and bone marrow function, and a left ventricular ejection fraction of 55% or higher measured by echocardiography Exclusion Criteria: * An ineligibility to participate in the clinical study based on the judgment of investigators from a legal perspective * A past history of chemotherapy * tumor with obstruction or perforation * tumor with distant metastases * synchronous tumor * relative or absolute contraindications of chemotherapy * Recent MI, CVA, nitrate medication * Severe cardiovascular disease, psychiatric disease * Severe hepatic dysfunction (GOT, GPT ≥100IU/L) * Renal dysfunction (Cr ≥2mg/dl) * The concurrent presence of other severe medical diseases

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colon cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colon carcinoma colonic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colon cancer

Contacts and locations

Locations

  • Jun Seok Park

    Daegu, South Korea

  • Kyungpook National University Medical center

    Daegu, 41404, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.